Entera Bio Is Building the Future of Peptides Beyond the Needle (NASDAQ: ENTX)

NY, WSW, June 1st, 2026, FinanceWire

Peptides are having a moment - and for good reason. They represent one of the most productive frontiers in modern medicine: naturally occurring molecules, engineered into therapies that have genuinely changed lives. Insulin is a peptide. So is the GLP-1 class - Ozempic, Wegovy, Mounjaro - that has reshaped how the world treats diabetes and obesity and put the word "peptide" into the cultural bloodstream. The science is real, the breakthroughs are real, and the investment dollars have followed.

But every gold rush attracts prospectors, which is what makes one largely overlooked company so interesting. While TikTok influencers hawk BPC-157 with affiliate codes and longevity evangelists like Bryan Johnson catalogue the compounds they inject, most of it backed by little to no rigorous human clinical data. On the other hand, Entera Bio (NASDAQ: ENTX) has quietly spent years doing the hard thing: building a proprietary platform to enable one of most robust pipelines of oral peptides out there.

The wellness wave is enormous. Videos tagged "peptides" have topped 50 million views; searches for longevity peptides have climbed roughly 300% in a year. But Eric Topol, director of the Scripps Research Translational Institute, has called the use of unproven grey-market peptides "unfounded and reckless." The gap between what's proven and what's being sold is vast, and widening. Entera sits on the other side of it.

Entera's N-Tab platform exists to solve the challenge that has defined peptide medicine for decades: therapeutics peptides work, but they've historically required injection. Entera turns them into oral tablets, and has now done so across multiple targets.

Its lead candidate, EB613, is designed to be the first oral anabolic (bone-building) tablet for osteoporosis. The disease affects an estimated 200 million women worldwide, and osteoporosis-related fractures put more women in the hospital than heart attack, stroke, and breast cancer combined. The most effective therapies, anabolics, already exist. Eli Lilly's injectable Forteo generated roughly $1.7 billion in peak annual sales, yet it is estimated that fewer than one in ten high-risk patients ever receives one. The barrier has never been the biology. It's the needle. EB613 delivers the same hormone as Forteo, PTH(1-34), in a once-daily pill. In a 161-patient Phase 2 study published in the Journal of Bone and Mineral Research, it produced statistically significant bone-density gains at the spine, femoral neck, and total hip - building bone while reducing its breakdown.

In March 2026, Entera submitted a streamlined Phase 3 protocol: roughly 750 patients, a 12-month primary endpoint in addition to a 12-month extension study, and critically, its next-generation single tablet as the candidate.

Entera's earlier work used a multi-tablet regimen; the version now headed into the pivotal study is a single, once-daily commercial tablet, bridged back to both the multi-tablet data and to Forteo itself. The significance is twofold. First, it removes a layer of late-stage risk - the asset being tested is the asset that would reach the market, with no formulation change left to make. Second, and arguably bigger commercially: in a chronic, asymptomatic disease where adherence is everything, a single daily pill rather than a handful is what turns proven biology into real-world uptake - and a far larger market.

That is exactly the data the field just chose to elevate. On May 28, Entera announced that its EB613 single-tablet results had been selected for a Late-Breaking Oral Presentation at ENDO 2026 (the Endocrine Society's annual meeting), the field's most prestigious gathering - in Chicago on June 14. At a conference where the overwhelming majority of accepted science is relegated to poster boards, an oral slot is reserved for work the field's own experts consider most consequential. The title says it plainly: Transforming Anabolic Treatments for Osteoporosis: New Clinical Data Supports a Single EB613 Tablet as the Final Candidate for a Phase 3 Study. Two more programs, EB612 for hypoparathyroidism and EB618, an oral GLP-1/glucagon tablet for obesity and metabolic disease, were accepted alongside it for poster presentations.

The market has noticed at the edges. BVF Partners, the specialist biotech fund behind ChemoCentryx and Blueprint Medicines, led a $10 million investment in April with up to $24.5 million in potential proceeds. Former Pfizer Group President Geno Germano, who once ran a ~$14 billion innovative-medicines portfolio, joined as Chairman in February. The CEO and multiple board members have been buying stock in the open market.

So here's the contrast worth sitting with. The peptide conversation is dominated by names you've heard, selling things with no clinical proof. The company actually advancing proprietary oral peptides through late-stage development, onto the FDA's desk, and onto the main stage at ENDO, is one most investors haven't heard of yet. Its entire market cap is hovering below $70 million.

The crowd is chasing the buzz. The science is somewhere else entirely.

Read this Next >>

Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026 (NASDAQ: ARWR)

Novo Nordisk A/S announces share repurchase programme (NYSE: NVO)

Recent News Highlights from Entera Bio (ENTX)

Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation

Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs

Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613

Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. Wall Street Wire is not a broker-dealer or investment adviser. References to market size estimates, valuations, price targets, or other third-party data are provided strictly for informational purposes. Wall Street Wire receives cash compensation from Entera Bio Ltd. (the “Issuer”) for coverage and awareness services, which are provided on an ongoing subscription basis. The content above is a form of paid advertising and promotion and is for informational purposes only and does not constitute financial or investment advice. This article may contain forward-looking statements about the Issuer's products, plans, or prospects that are subject to risks and uncertainties; actual results may differ materially, and readers should review the Issuer's public filings on SEC EDGAR (sec.gov/edgar) for full risk factors. Market size figures, research estimates, or other third-party data referenced in this article are quoted from publicly available sources believed to be reliable; however, we do not independently verify or endorse them, and additional figures or estimates may exist. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. This article should not be considered an official communication of the Issuer. Images may be computer generated and are for entertainment and visualization purposes only, and may not be an accurate or exact depiction of the technology.

Contact